Loading…
Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145
Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this stud...
Saved in:
Published in: | Biomedicine & pharmacotherapy 2016-10, Vol.83, p.1105-1110 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3 |
---|---|
cites | cdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3 |
container_end_page | 1110 |
container_issue | |
container_start_page | 1105 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 83 |
creator | Sun, Keming Wang, Junjian Liu, Fangna Ji, Zejuan Guo, Zhanhao Zhang, Chunxu Yao, Manye |
description | Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145. |
doi_str_mv | 10.1016/j.biopha.2016.08.025 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835532046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0753332216307284</els_id><sourcerecordid>1835532046</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</originalsourceid><addsrcrecordid>eNqFkUtv1TAQhS0EoreFf4CQl2wS_Ijz2CChqkClSpV4rC3HGd_6ksTB4yBdfj2OUliwYeXx6JwZnW8IecVZyRmv357K3oflwZQi_0rWlkyoJ-TAO8WKmrHmKTmwRslCSiEuyCXiiTGmatk-JxeiUYo3qj6QX_eIIfkB6BLDFBIgtTCOdPDOQYQ5eZN8mGlw9GGdTC4wQehHgwmpy5a9cYQZ0CP10wLRgU2GLtmY_Uj7M12XIsJxHXNrPtLJfy54pV6QZ86MCC8f3yvy7cPN1-tPxd39x9vr93eFrXiTCmgtdKoSfc2UtBUTXdsN0LRDV7dOdsoM3NbSNqKtjLIgDTcdU6pyfd91yjl5Rd7sc3PCHytg0pPHLaSZIayoeSuVkoJVdZZWu9TGgBjB6SX6ycSz5kxv1PVJ79T1Rl2zVmfq2fb6ccPaTzD8Nf3BnAXvdgHknD89RI02w7Ew-Jhh6SH4_234d4Ad_eytGb_DGfAU1jhnhpprFJrpL9vlt8PzWrKNjPwN2DOsKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835532046</pqid></control><display><type>article</type><title>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</title><source>Elsevier</source><creator>Sun, Keming ; Wang, Junjian ; Liu, Fangna ; Ji, Zejuan ; Guo, Zhanhao ; Zhang, Chunxu ; Yao, Manye</creator><creatorcontrib>Sun, Keming ; Wang, Junjian ; Liu, Fangna ; Ji, Zejuan ; Guo, Zhanhao ; Zhang, Chunxu ; Yao, Manye</creatorcontrib><description>Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2016.08.025</identifier><identifier>PMID: 27551756</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Case-Control Studies ; Cell Differentiation - drug effects ; Cell Proliferation - drug effects ; Complex Mixtures - pharmacology ; Core Binding Factor Alpha 1 Subunit - genetics ; Core Binding Factor Alpha 1 Subunit - metabolism ; Differentiation ; Disease Progression ; Down-Regulation - drug effects ; Humans ; Internal Medicine ; Medical Education ; MicroRNAs - genetics ; MicroRNAs - metabolism ; MiR-145 ; Ossotide ; Osteoblasts ; Osteoblasts - drug effects ; Osteoblasts - metabolism ; Osteoblasts - pathology ; Osteogenesis Imperfecta - genetics ; Osteogenesis Imperfecta - pathology ; Runx2 ; Up-Regulation - drug effects ; Up-Regulation - genetics ; Wnt Signaling Pathway - drug effects</subject><ispartof>Biomedicine & pharmacotherapy, 2016-10, Vol.83, p.1105-1110</ispartof><rights>Elsevier Masson SAS</rights><rights>2016 Elsevier Masson SAS</rights><rights>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</citedby><cites>FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27551756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Keming</creatorcontrib><creatorcontrib>Wang, Junjian</creatorcontrib><creatorcontrib>Liu, Fangna</creatorcontrib><creatorcontrib>Ji, Zejuan</creatorcontrib><creatorcontrib>Guo, Zhanhao</creatorcontrib><creatorcontrib>Zhang, Chunxu</creatorcontrib><creatorcontrib>Yao, Manye</creatorcontrib><title>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.</description><subject>Case-Control Studies</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Complex Mixtures - pharmacology</subject><subject>Core Binding Factor Alpha 1 Subunit - genetics</subject><subject>Core Binding Factor Alpha 1 Subunit - metabolism</subject><subject>Differentiation</subject><subject>Disease Progression</subject><subject>Down-Regulation - drug effects</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - metabolism</subject><subject>MiR-145</subject><subject>Ossotide</subject><subject>Osteoblasts</subject><subject>Osteoblasts - drug effects</subject><subject>Osteoblasts - metabolism</subject><subject>Osteoblasts - pathology</subject><subject>Osteogenesis Imperfecta - genetics</subject><subject>Osteogenesis Imperfecta - pathology</subject><subject>Runx2</subject><subject>Up-Regulation - drug effects</subject><subject>Up-Regulation - genetics</subject><subject>Wnt Signaling Pathway - drug effects</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1TAQhS0EoreFf4CQl2wS_Ijz2CChqkClSpV4rC3HGd_6ksTB4yBdfj2OUliwYeXx6JwZnW8IecVZyRmv357K3oflwZQi_0rWlkyoJ-TAO8WKmrHmKTmwRslCSiEuyCXiiTGmatk-JxeiUYo3qj6QX_eIIfkB6BLDFBIgtTCOdPDOQYQ5eZN8mGlw9GGdTC4wQehHgwmpy5a9cYQZ0CP10wLRgU2GLtmY_Uj7M12XIsJxHXNrPtLJfy54pV6QZ86MCC8f3yvy7cPN1-tPxd39x9vr93eFrXiTCmgtdKoSfc2UtBUTXdsN0LRDV7dOdsoM3NbSNqKtjLIgDTcdU6pyfd91yjl5Rd7sc3PCHytg0pPHLaSZIayoeSuVkoJVdZZWu9TGgBjB6SX6ycSz5kxv1PVJ79T1Rl2zVmfq2fb6ccPaTzD8Nf3BnAXvdgHknD89RI02w7Ew-Jhh6SH4_234d4Ad_eytGb_DGfAU1jhnhpprFJrpL9vlt8PzWrKNjPwN2DOsKA</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Sun, Keming</creator><creator>Wang, Junjian</creator><creator>Liu, Fangna</creator><creator>Ji, Zejuan</creator><creator>Guo, Zhanhao</creator><creator>Zhang, Chunxu</creator><creator>Yao, Manye</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161001</creationdate><title>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</title><author>Sun, Keming ; Wang, Junjian ; Liu, Fangna ; Ji, Zejuan ; Guo, Zhanhao ; Zhang, Chunxu ; Yao, Manye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Case-Control Studies</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Complex Mixtures - pharmacology</topic><topic>Core Binding Factor Alpha 1 Subunit - genetics</topic><topic>Core Binding Factor Alpha 1 Subunit - metabolism</topic><topic>Differentiation</topic><topic>Disease Progression</topic><topic>Down-Regulation - drug effects</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - metabolism</topic><topic>MiR-145</topic><topic>Ossotide</topic><topic>Osteoblasts</topic><topic>Osteoblasts - drug effects</topic><topic>Osteoblasts - metabolism</topic><topic>Osteoblasts - pathology</topic><topic>Osteogenesis Imperfecta - genetics</topic><topic>Osteogenesis Imperfecta - pathology</topic><topic>Runx2</topic><topic>Up-Regulation - drug effects</topic><topic>Up-Regulation - genetics</topic><topic>Wnt Signaling Pathway - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Keming</creatorcontrib><creatorcontrib>Wang, Junjian</creatorcontrib><creatorcontrib>Liu, Fangna</creatorcontrib><creatorcontrib>Ji, Zejuan</creatorcontrib><creatorcontrib>Guo, Zhanhao</creatorcontrib><creatorcontrib>Zhang, Chunxu</creatorcontrib><creatorcontrib>Yao, Manye</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Keming</au><au>Wang, Junjian</au><au>Liu, Fangna</au><au>Ji, Zejuan</au><au>Guo, Zhanhao</au><au>Zhang, Chunxu</au><au>Yao, Manye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>83</volume><spage>1105</spage><epage>1110</epage><pages>1105-1110</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Abstract Ossotide as an effective bone formation compound preparation has been proved to promote osteoblasts differentiation. MiR-145 is significantly decreased in osteogenesis imperfecta (OI) patients, but it is still unknown whether ossotide performed its effect by regulating miR-145. In this study, we investigated the effect of ossotide on regulating miR-145 expression and osteoblasts differentiation. The primary osteoblasts cells were isolated from OI patients and then cultured with different concentrations (0, 25, 50, 100, 200 μg/l) of ossotide. The cell proliferation was detected with CCK-8 Elisa kit after ossotide treatment. The level of miR-145 expression was determined using qRT-PCR. In order to study whether ossotide up regulated miR-145, miR-145 mimic and miR-145 inhibitor were used to up regulate and down regulate the miR-145 levels in osteoblasts. The expressions of Runx2, Osx, β-catenin, TCF-1 were detected using Western blot and qRT-PCR. We observed that miR-145 was up regulated by ossotide treatment in miR-145 mimic or miR-145 inhibitor treated osteoblasts. What’s more, up regulated miR-145 increased the expression of osteoblasts differentiation regulated protein Runx2 and Osx. In addition, Wnt signaling related β-catenin, TCF-1 were activated by up-regulated miR-145 which was induced by ossotide treatment. In summary, ossotide induced cell differentiation and Wnt signaling activation in osteoblasts by up regulating miR-145.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>27551756</pmid><doi>10.1016/j.biopha.2016.08.025</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2016-10, Vol.83, p.1105-1110 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_1835532046 |
source | Elsevier |
subjects | Case-Control Studies Cell Differentiation - drug effects Cell Proliferation - drug effects Complex Mixtures - pharmacology Core Binding Factor Alpha 1 Subunit - genetics Core Binding Factor Alpha 1 Subunit - metabolism Differentiation Disease Progression Down-Regulation - drug effects Humans Internal Medicine Medical Education MicroRNAs - genetics MicroRNAs - metabolism MiR-145 Ossotide Osteoblasts Osteoblasts - drug effects Osteoblasts - metabolism Osteoblasts - pathology Osteogenesis Imperfecta - genetics Osteogenesis Imperfecta - pathology Runx2 Up-Regulation - drug effects Up-Regulation - genetics Wnt Signaling Pathway - drug effects |
title | Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ossotide%20promotes%20cell%20differentiation%20of%20human%20osteoblasts%20from%20osteogenesis%20imperfecta%20patients%20by%20up-regulating%20miR-145&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Sun,%20Keming&rft.date=2016-10-01&rft.volume=83&rft.spage=1105&rft.epage=1110&rft.pages=1105-1110&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2016.08.025&rft_dat=%3Cproquest_cross%3E1835532046%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-e8ce9542b6053c402989de78d968f395ad1c63c7284a5ce3a1a90554fbb995ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835532046&rft_id=info:pmid/27551756&rfr_iscdi=true |